ShopTake the QUIZBest SellersNon-PrescriptionMen'sMaximum StrengthBalanced Results & SafetyLow Dose FinasterideNaturalNew PathwaysView AllWomen'sMaximum StrengthBalanced Results & SafetyThyroid-RelatedNaturalView AllShop AllTopicalsTablets
RewardsCommunity
ExploreResearchTreatment ScienceAll BlogsVideos
About UsAbout UsCommunity ForumContactFAQ
Quick Links
Off-LabelB

Dutasteride

Dutasteride (Avodart)

Most potent 5-alpha reductase inhibitor with RCT evidence of superiority over finasteride.

BEvidence grade
10Claims evaluated
6Key human trials
4 / 5Strength for hair
Mechanism & evidence strength

How Dutasteride works — and how well we know it

Mechanism of action

Dutasteride competitively and irreversibly inhibits both Type I and Type II 5-alpha reductase isoenzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT). Type I is found in sebaceous glands, sweat glands, and scalp keratinocytes (~33% of circulating DHT). Type II is found in the prostate and male genital tract (~66% of circulating DHT). By blocking both, dutasteride achieves ~90-98% serum DHT suppression at 0.5mg daily, compared to ~70% for finasteride (Type II only). Dutasteride is approximately 3x more potent than finasteride at inhibiting Type I and 100x more potent at inhibiting Type II.

5-alpha reductase Type I & IIDHT reduction (~90–98%)
Route

oral, topical, mesotherapy injection

Typical dose

Oral: 0.5 mg daily. Topical: 0.05% solution.

Regulatory status

FDA-approved for BPH. Approved for AGA in South Korea, Japan, Taiwan. Off-label elsewhere.

Best for

Second-line treatment or patients seeking maximum DHT suppression.

Evidence distribution across 10 claims

In Silico—
In Vitro—
In Vivo—
Ex Vivo—
Open-Label3
RCT7

Why the grade is B. Efficacy actually supports an A (multiple RCTs show superiority over finasteride); the grade is held to B by its off-label status (not FDA-approved for AGA in the US/EU) and more limited long-term safety data in young men than finasteride.

Efficacy

What the trials actually showed

Olsen 2006 (Phase II dose-ranging)RCT
N: · 24 weeks
416 men aged 21-45 with AGA
Endpoint:
Gubelin Harcha 2014 / ARIA Trial (Phase III)RCT
N: · 24 weeks
917 men aged 20-50 with AGA (largest head-to-head trial)
Endpoint:
Eun 2010 (Korean Phase III)RCT
N: · 24 weeks
153 Korean men with AGA
Endpoint:
Shanshanwal 2017 (Head-to-head with miniaturization data)RCT
N: · 24 weeks
90 men with AGA
Endpoint:
Shin 2022 / Lee 2024 (Long-term Korean multicenter)OBSERVATIONAL
N: · Up to 5 years
467 Korean men with AGA
Endpoint:
Lee 2025 (Low-dose Phase III)RCT
N: · 24 weeks
139 Korean men with AGA
Endpoint:
Time to effect

DHT suppression begins immediately, but clinical hair changes require 3-6 months to become visible. Most RCTs assess at 24 weeks. Initial shedding may occur in the first 1-3 months as miniaturized hairs are replaced. Due to the 4-5 week half-life, steady-state serum concentration is not reached until approximately 6 months (65% at 1 month, 90% at 3 months). Clinical improvement continues beyond 6 months, with optimal results typically at 12+ months.

Peak effect

Most clinical trials measure at 24 weeks and show robust efficacy. Long-term data suggests continued improvement up to 12 months, with stabilization/maintenance thereafter. The 5-year Korean data (89.9% improvement rate) suggests sustained benefit with no tachyphylaxis. Peak hair count improvement likely occurs at 12-24 months based on the pharmacokinetic profile and hair cycle biology.

Maintenance

Yes — must continue indefinitely

If stopped

Hair loss resumes gradually after discontinuation but much more slowly than with finasteride due to the 4-5 week half-life. One week post-cessation, dutasteride maintains ~90% serum DHT suppression (mean 38.3 pg/mL) vs finasteride which shows only 35% suppression (mean 324.8 pg/mL). Detectable drug levels persist 4-6 months after last dose. Full washout takes 6+ months. Blood donation is prohibited for 6 months after last dose due to teratogenic risk.

Safety profile

Side effects, contraindications, and special populations

FDA black-box warning
None. However, the FDA label includes a warning about the increased incidence of high-grade prostate cancer observed in the REDUCE trial (BPH prevention study in older men). This is not a black box warning but is prominently included in prescribing information.
Common adverse events for Dutasteride
Adverse eventRatePlaceboNotes
Decreased libido1-6% (AGA trials); 3% vs 1.4% placebo (BPH prescribing information, first 6 months)—Most common early in treatment. Incidence decreases over time: from ~3% in year 1 to <1% in year 4 of BPH trials. Rates in AGA trials are comparable to finasteride. In the low-dose (0.2mg) Phase III trial, libido effects were not statistically different from placebo.
Erectile dysfunction1-5% (AGA trials); 4.7% vs 1.7% placebo (BPH prescribing information, first 6 months); 3.57% at 0.2mg, 14.29% at 0.5mg (small Korean Phase III)—Most frequently reported sexual AE. Rates vary across trials, likely influenced by nocebo effect (sexual AE rates in placebo arms are 5-8%). The 0.2mg dose showed rates comparable to placebo. Most cases are mild-to-moderate and resolve during treatment or after discontinuation.
Ejaculation disorders (decreased volume, retrograde)1-5% (AGA trials); 1.4% vs 0.5% placebo (BPH prescribing information, first 6 months)—Includes decreased ejaculate volume and altered ejaculation. Consistent with mechanism (DHT is involved in seminal vesicle function). Generally mild.
Breast disorders (gynecomastia and/or breast tenderness)0.3-1% (AGA trials); 0.5% vs 0.2% placebo (BPH prescribing information, first 6 months); up to 1.9% in the REDUCE BPH trial—Gynecomastia results from increased testosterone-to-estrogen conversion when DHT pathway is blocked. Generally reversible on discontinuation. Incidence is low at AGA doses.
Semen parameter changesDecreased sperm count and semen volume reported in healthy volunteer studies—Total sperm count decreased at 26 weeks. Semen volume decreased at 52 weeks. Short-term use (<17 months): effects appear reversible after discontinuation. Long-term use (>17-20 months): may persistently impair semen volume and sperm motility. Effects on fertility are formally unknown. Men planning to conceive should discuss with physician.
Serious adverse events
  • High-grade prostate cancer signal (REDUCE trial) (In the REDUCE BPH prevention trial (n=6,729): 12 Gleason 8-10 tumors in dutasteride group vs 1 in placebo group (p<0.003) during years 3-4) — This was a BPH cancer prevention trial in older men (mean age ~62), not an AGA trial. Overall prostate cancer was reduced by 22.5% with dutasteride. The high-grade signal is debated -- may reflect detection bias (dutasteride shrinks the prostate, making biopsies more likely to sample aggressive tumors). FDA added a warning to the label. Relevance to young men using dutasteride for AGA at 0.5mg is uncertain but should be disclosed.
  • Persistent sexual dysfunction (post-5ARI syndrome) (Unknown; not established in controlled trials. Reported in case series and pharmacovigilance databases.) — A subset of patients report persistent sexual, neurological, and psychological symptoms after discontinuation of 5-alpha reductase inhibitors. This is recognized by the EMA but not fully characterized. Causality is debated. Dutasteride's long half-life means any side effects take much longer to resolve (weeks-months vs days for finasteride), which may confound reports of 'persistence.'
  • Depression / mood changes (~1-2% in pharmacovigilance data; no consistent signal in RCTs) — Less evidence linking dutasteride to depression compared to finasteride. Monitoring for mood changes is recommended. No direct causal link established in controlled trials. Neurosteroid disruption from 5AR inhibition (allopregnanolone depletion) is a proposed mechanism.
  • Allergic reactions (angioedema, urticaria) (Rare (<0.1%)) — Reported in post-marketing surveillance. Includes angioedema, localized edema, skin rash, pruritus, and urticaria.
Contraindications
  • Pregnancy or potential pregnancy -- absolutely contraindicated (teratogenic: causes feminization of male fetus external genitalia, decreased prostatic and seminal vesicular weights, nipple development in animal studies)
  • Women of childbearing potential must not handle broken or leaking dutasteride capsules (drug is absorbed through skin)
  • Hypersensitivity to dutasteride, other 5-alpha reductase inhibitors (including finasteride), or any excipient
  • Pediatric patients (safety and efficacy not established in children)
  • Blood donation prohibited for at least 6 months after last dose to prevent exposure of pregnant transfusion recipient
Drug interactions
  • CYP3A4 inhibitors (strong) (Use with caution; may increase dutasteride exposure and side effect risk) — Ritonavir, ketoconazole, itraconazole, ceritinib
  • CYP3A4 inhibitors (moderate) (Clinical significance uncertain; monitoring recommended) — Verapamil, diltiazem, ciprofloxacin, fluconazole, cimetidine
  • Alpha-blockers (tamsulosin, doxazosin, terazosin) (No dose adjustment needed) — Tamsulosin, doxazosin, terazosin
Pregnancy

Absolutely contraindicated. Category X (AU TGA). Dutasteride is teratogenic -- exposure during pregnancy causes feminization of male fetus (abnormal external genitalia, decreased prostatic and seminal vesicular weights, nipple development in animal models). Even skin contact with broken capsules poses risk. Blood donation prohibited for 6 months post-treatment. Stricter than finasteride in practice due to the 4-5 week half-life: a man switching from dutasteride to attempt conception needs 6+ months washout, vs days for finasteride.

Women

Not approved for use in women. Contraindicated in women of childbearing potential. Very limited data from mesotherapy studies (intradermal injection, no systemic absorption). Not studied in oral form for female pattern hair loss. Women must not handle broken capsules.

Children

Contraindicated. Safety and efficacy not established in pediatric patients.

Elderly

No dose adjustment required for age >=65. Half-life is longer in elderly men (300 hours for >70 years vs 170 hours for 20-49 years). Not typically relevant for AGA treatment population.

Renal impairment

No dose adjustment required. <1% excreted renally.

Hepatic impairment

Use with caution in severe hepatic impairment. Dutasteride is extensively hepatically metabolized via CYP3A4/5. No formal dose adjustment in labeling but exposure may be increased.

fertilityConsiderations

Decreases total sperm count, semen volume, and sperm motility. Short-term effects (under ~17 months) appear reversible after discontinuation. Long-term use (>17-20 months) may cause persistent impairment of semen volume and motility. Men actively trying to conceive should discuss risks with physician and consider switching to finasteride (shorter half-life, faster washout) or discontinuing.

Evidence breakdown

Every claim, traced back to its source

We took every major claim made about Dutasteride and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.

10 claims · evidence-by-evidence breakdown

1
Open-LabelWeight: Highest
Dutasteride inhibits both Type I and Type II 5-alpha reductase, achieving ~90-98% serum DHT suppression
Dutasteride at 0.5mg daily suppresses serum DHT by approximately 90-98%, compared to ~70% for finasteride 1mg. Dutasteride is 3x more potent than finasteride at inhibiting Type I 5AR and 100x more pot
The experimental model

In vivo (human pharmacokinetic/pharmacodynamic studies)

The finding

Dutasteride at 0.5mg daily suppresses serum DHT by approximately 90-98%, compared to ~70% for finasteride 1mg. Dutasteride is 3x more potent than finasteride at inhibiting Type I 5AR and 100x more potent at Type II. Scalp DHT is also suppressed to a greater degree than with finasteride.

Our assessment

Dutasteride at 0.5mg daily suppresses serum DHT by approximately 90-98%, compared to ~70% for finasteride 1mg. Dutasteride is 3x more potent than finasteride at inhibiting Type I 5AR and 100x more potent at Type II. Scalp DHT is also suppressed to a greater degree than with finasteride.

Citations
  • Clark RV et al (2004)
2
RCTWeight: Highest
Dutasteride 0.5mg is superior to finasteride 1mg for hair count and width in the largest head-to-head RCT (n=917)
At 24 weeks, dutasteride 0.5mg significantly increased hair count (p=0.003), hair width (p=0.004), and global photographic assessment (p=0.002) versus finasteride 1mg. All dutasteride doses were super
The experimental model

Human RCT (Phase III, double-blind, placebo- and active-controlled)

The finding

At 24 weeks, dutasteride 0.5mg significantly increased hair count (p=0.003), hair width (p=0.004), and global photographic assessment (p=0.002) versus finasteride 1mg. All dutasteride doses were superior to placebo. Hair count and width increases were dose-dependent. Adverse events were similar across all groups.

Our assessment

At 24 weeks, dutasteride 0.5mg significantly increased hair count (p=0.003), hair width (p=0.004), and global photographic assessment (p=0.002) versus finasteride 1mg. All dutasteride doses were superior to placebo. Hair count and width increases were dose-dependent. Adverse events were similar across all groups.

Citations
  • Gubelin Harcha W et al (2014)
3
RCTWeight: Highest
Dose-ranging data shows a direct relationship between DHT suppression and hair count increase
In 416 men, dutasteride (0.05-2.5mg) increased hair count dose-dependently. Dutasteride 2.5mg was superior to finasteride 5mg at both 12 and 24 weeks. Serum and scalp DHT suppression was inversely cor
The experimental model

Human RCT (Phase II, double-blind, placebo-controlled)

The finding

In 416 men, dutasteride (0.05-2.5mg) increased hair count dose-dependently. Dutasteride 2.5mg was superior to finasteride 5mg at both 12 and 24 weeks. Serum and scalp DHT suppression was inversely correlated with hair count improvement.

Our assessment

In 416 men, dutasteride (0.05-2.5mg) increased hair count dose-dependently. Dutasteride 2.5mg was superior to finasteride 5mg at both 12 and 24 weeks. Serum and scalp DHT suppression was inversely correlated with hair count improvement.

Citations
  • Olsen EA et al (2006)
4
RCTWeight: Highest
A Korean Phase III trial confirmed dutasteride 0.5mg efficacy with +12.2 hairs/cm2 vs +4.7 for placebo
In 153 Korean men, dutasteride 0.5mg daily for 24 weeks increased hair count by 12.2/cm2 versus 4.7/cm2 for placebo (p=0.0319). Significantly higher efficacy by self-assessment, investigator assessmen
The experimental model

Human RCT (Phase III, double-blind, placebo-controlled)

The finding

In 153 Korean men, dutasteride 0.5mg daily for 24 weeks increased hair count by 12.2/cm2 versus 4.7/cm2 for placebo (p=0.0319). Significantly higher efficacy by self-assessment, investigator assessment, and panel photography. This trial contributed to South Korean regulatory approval.

Our assessment

In 153 Korean men, dutasteride 0.5mg daily for 24 weeks increased hair count by 12.2/cm2 versus 4.7/cm2 for placebo (p=0.0319). Significantly higher efficacy by self-assessment, investigator assessment, and panel photography. This trial contributed to South Korean regulatory approval.

Citations
  • Eun HC et al (2010)
5
RCTWeight: High
Dutasteride is superior to finasteride in both hair regrowth (+23 vs +4/cm2) and miniaturization reversal
In 90 men over 24 weeks, dutasteride increased total hair count by 23 hairs/cm2 vs 4 for finasteride. Miniaturized hair decreased by 8/cm2 vs 1 for finasteride. Side effect profiles were similar betwe
The experimental model

Human RCT (open-label, evaluator-blinded)

The finding

In 90 men over 24 weeks, dutasteride increased total hair count by 23 hairs/cm2 vs 4 for finasteride. Miniaturized hair decreased by 8/cm2 vs 1 for finasteride. Side effect profiles were similar between groups.

Our assessment

In 90 men over 24 weeks, dutasteride increased total hair count by 23 hairs/cm2 vs 4 for finasteride. Miniaturized hair decreased by 8/cm2 vs 1 for finasteride. Side effect profiles were similar between groups.

Citations
  • Shanshanwal SJ, Dhurat RS (2017)
6
Open-LabelWeight: High
Long-term use shows ~90% improvement rate and ~94% disease-prevention rate at 5 years
In 467 Korean men, 89.9% of dutasteride-treated patients showed improvement and 93.9% achieved prevention of disease progression over 5 years. Dutasteride showed significantly greater improvement than
The experimental model

Retrospective chart review (multicenter, South Korea)

The finding

In 467 Korean men, 89.9% of dutasteride-treated patients showed improvement and 93.9% achieved prevention of disease progression over 5 years. Dutasteride showed significantly greater improvement than finasteride in BASP basic M and specific V pattern types.

Our assessment

In 467 Korean men, 89.9% of dutasteride-treated patients showed improvement and 93.9% achieved prevention of disease progression over 5 years. Dutasteride showed significantly greater improvement than finasteride in BASP basic M and specific V pattern types.

Citations
  • Shin JW et al (2022)
7
RCTWeight: High
Intermittent dosing (2-3x/week) may match daily finasteride due to dutasteride's long half-life
In 60 men over 24 weeks: thrice-weekly dutasteride +17.43 hairs/cm2, daily finasteride +12.81 hairs/cm2, twice-weekly dutasteride +7.74 hairs/cm2. Thrice-weekly dutasteride showed 35% moderate-to-mark
The experimental model

Human RCT (pilot, investigator-blinded, active-controlled)

The finding

In 60 men over 24 weeks: thrice-weekly dutasteride +17.43 hairs/cm2, daily finasteride +12.81 hairs/cm2, twice-weekly dutasteride +7.74 hairs/cm2. Thrice-weekly dutasteride showed 35% moderate-to-marked improvement vs 21% for daily finasteride. Sexual side effects were similar across all groups.

Our assessment

In 60 men over 24 weeks: thrice-weekly dutasteride +17.43 hairs/cm2, daily finasteride +12.81 hairs/cm2, twice-weekly dutasteride +7.74 hairs/cm2. Thrice-weekly dutasteride showed 35% moderate-to-marked improvement vs 21% for daily finasteride. Sexual side effects were similar across all groups.

Citations
  • Rathnayake D et al (2025)
8
RCTWeight: High
Topical dutasteride 0.05% outperforms oral finasteride 1mg with minimal systemic absorption
In 135 men over 24 weeks: topical dutasteride 0.05% achieved +75.52 hairs/cm2, oral finasteride +41.21, placebo +0.07. Patient-reported improvement: 93.1% vs 71.4%. Plasma dutasteride levels near or b
The experimental model

Human RCT (Phase II, double-blind, placebo- and active-controlled)

The finding

In 135 men over 24 weeks: topical dutasteride 0.05% achieved +75.52 hairs/cm2, oral finasteride +41.21, placebo +0.07. Patient-reported improvement: 93.1% vs 71.4%. Plasma dutasteride levels near or below quantification limits (max 169 pg/mL). Serum DHT decreased only ~11% (vs ~27% for oral finasteride). Zero adverse events reported in any active group.

Our assessment

In 135 men over 24 weeks: topical dutasteride 0.05% achieved +75.52 hairs/cm2, oral finasteride +41.21, placebo +0.07. Patient-reported improvement: 93.1% vs 71.4%. Plasma dutasteride levels near or below quantification limits (max 169 pg/mL). Serum DHT decreased only ~11% (vs ~27% for oral finasteride). Zero adverse events reported in any active group.

Citations
  • Mundhe G et al (2025)
9
Open-LabelWeight: Moderate
Dutasteride mesotherapy shows improvement with no systemic hormone changes
In the pilot study, all 6 patients showed increased hair density and diameter with no changes in serum hormone levels. In 126 women, 62.8% showed improvement vs 17.5% in saline control. Treatment prot
The experimental model

Mixed: prospective pilot study (n=6), retrospective clinical series, controlled trial in women (n=126)

The finding

In the pilot study, all 6 patients showed increased hair density and diameter with no changes in serum hormone levels. In 126 women, 62.8% showed improvement vs 17.5% in saline control. Treatment protocol: intradermal 0.01% dutasteride, 1mL every 3 months. No adverse effects recorded.

Our assessment

In the pilot study, all 6 patients showed increased hair density and diameter with no changes in serum hormone levels. In 126 women, 62.8% showed improvement vs 17.5% in saline control. Treatment protocol: intradermal 0.01% dutasteride, 1mL every 3 months. No adverse effects recorded.

Citations
  • Saceda-Corralo D et al (2017)
10
RCTWeight: Highest
Low-dose dutasteride (0.2mg) is as effective as 0.5mg with a safety profile comparable to placebo
In 139 Korean men over 24 weeks, 0.2mg dutasteride matched 0.5mg on all efficacy endpoints (hair count, photographic assessment, subjective improvement). Adverse event incidence in the 0.2mg group was
The experimental model

Human RCT (Phase III, double-blind, placebo-controlled)

The finding

In 139 Korean men over 24 weeks, 0.2mg dutasteride matched 0.5mg on all efficacy endpoints (hair count, photographic assessment, subjective improvement). Adverse event incidence in the 0.2mg group was not statistically different from placebo.

Our assessment

In 139 Korean men over 24 weeks, 0.2mg dutasteride matched 0.5mg on all efficacy endpoints (hair count, photographic assessment, subjective improvement). Adverse event incidence in the 0.2mg group was not statistically different from placebo.

Citations
  • Lee WS et al (2025)
Open questions

What's still missing from the science

  • No FDA approval for AGA despite positive Phase III data (commercial decision, not evidence gap)
  • No head-to-head RCT data beyond 24 weeks comparing dutasteride to finasteride
  • Limited long-term safety data (>5 years) in young men (20-40) who are the primary AGA population
  • Topical dutasteride Phase III results not yet published (ongoing trials)
  • Long half-life (4-5 weeks) means slow washout -- side effects persist much longer than with finasteride
  • Extremely limited data in women with female pattern hair loss (Category X, teratogenic)
  • Post-finasteride syndrome concerns remain unresolved for all 5-alpha reductase inhibitors
  • Mesotherapy protocols are not standardized (concentration, volume, frequency vary across studies)
  • No data on long-term topical dutasteride safety or whether systemic absorption increases over years
Bottom line

Our verdict on Dutasteride

Strongest DHT suppression
Dutasteride is probably the most effective single drug for androgenetic alopecia based on RCT evidence. Multiple large trials demonstrate clear superiority over finasteride for hair count, hair width, and miniaturization reversal. A 2024 network meta-analysis ranked it as the most effective monotherapy. Its off-label status in the US and Europe, long half-life (4-5 weeks), and more limited long-term safety data in young men compared to finasteride mean it is typically used as a second-line option or for patients seeking maximum potency. Topical dutasteride and low-dose oral dutasteride are promising developments that may change the risk-benefit calculation.
Probably the most effective single drug for AGA based on RCT evidence.
How Anagen formulates it

Dutasteride at Anagen

Both routes the literature supports: standard 0.5 mg oral, and a topical at the lowest concentration with published trial data.

TopicalPrecision DutasterideDutasteride 0.03%Topical dutasteride at the lowest effective concentration validated in published trials.$80.00 / mo with a 12-month plan →Oral tabletDutasteride 0.5 mg tabletsDutasteride 0.5 mgStandard oral dutasteride. Suppresses both type I and type II 5-alpha reductase.$20.00 / mo with a 12-month plan →
Take the 60-second quiz →Browse all formulations
Go deeper

Long-form analysis and primary-source breakdowns that go beyond the summary above.

Compare

How does Dutasteride stack up against its closest peers?

KetoconazoleB

Well-tolerated adjunct with antifungal, anti-inflammatory, and potential anti-androgenic properties.

Read the breakdown →
LatanoprostC

Strong prostaglandin biology and one small positive RCT for scalp, but validated only for eyelash growth (via bimatoprost/Latisse)

Read the breakdown →
LevocetirizineC

Compelling PGD2-based rationale and consistently positive clinical signals with cetirizine, but no large definitive trial — best used as an adjunct to proven treatments

Read the breakdown →

← Back to all treatments